ClinConnect ClinConnect Logo
Search / Trial NCT03634930

Josef Ressel Centre Perinatal Programming

Launched by MOENIE VAN DER KLEYN · Aug 14, 2018

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Breast Feeding, Exclusive Versus Formula Feeding, Exclusive Satiety Cues Childhood Obesity Biomarker Nutritional Status Infant Body Composition Infant Weight Gain Velocity Metabolic Programming Inflammation

ClinConnect Summary

The Josef Ressel Centre Perinatal Programming trial is studying how early nutrition and maternal factors influence the risk of childhood obesity. Researchers believe that what mothers eat during pregnancy and how they feed their babies in the first few months of life can shape the child's health for years to come. The study aims to find out more about factors like breastfeeding, the amount of food babies drink, and how quickly they gain weight, to better understand their impact on obesity risk.

To participate, mothers must be pregnant or recently given birth, between 18 and 50 years old, and have a healthy weight (BMI between 18.5 and 30). They should also be non-smokers and able to speak German. Participants will be asked to keep feeding diaries, undergo weight measurements, and provide samples for analysis. Throughout the study, which spans from pregnancy until the child is two years old, mothers will have regular check-ins to track their baby’s growth and eating habits. This research could help identify ways to prevent obesity in children, making it an important step towards healthier futures.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Pregnancy or mother in puerperium
  • 2. Delivery of baby at 37+0 to 41+6 gestational age
  • 3. Legal age (18 years old), age limit 50 years
  • 4. Written consent of test person after having been informed
  • 5. BMI ≥ 18.5 kg/m² to \< 30 kg/m²
  • 6. Negative result of oGTT (oral glucose tolerance test) during pregnancy
  • 7. Birth weight of baby 2.5-4.5 kg
  • 8. Non-smoker since knowledge of pregnancy
  • 9. Very good knowledge of German language and Caucasian
  • 10. Exclusive breastfeeding or exclusive formula feeding at MR 2 (4th week of life)
  • Exclusion Criteria:
  • 1. Birth before 37+0 week of pregnancy (WoP) or after the 41+6 WoP
  • 2. Multiple pregnancy
  • 3. Children with serious congenital malformations of
  • Nervous system
  • Mouth, throat, neck
  • Circulation system
  • Respiratory tract
  • Gastrointestinal tract
  • Urogenital tract
  • Chromosomal aberrations
  • 4. Diseases or hospitalization or intensive medical care of child during neonatal period
  • 5. Hereditary metabolic diseases of child
  • Hereditary disorders of fat metabolism (MCHAD: Medium Chain Acyl-CoA Dehydrogenase Deficiency, LCHAD: Long Chain Acyl-CoA Dehydrogenase Deficiency, VLCHAD: Very Long Chain Acyl-CoA Dehydrogenase Deficiency)
  • Hereditary disorders of amino acid metabolism (PKU: Phenylketonuria)
  • Hereditary disorders of carbohydrate metabolism (Glycogenosis, Galactosemia, Hereditary fructose intolerance, Diabetes mellitus Type 1)
  • 6. Drug (tobacco) abuse
  • 7. Mental illnesses that have to be treated with medicaments
  • 8. Metabolic or autoimmune diseases of mother
  • 9. Complications at birth (blood loss \> 1000 ml or eclampsia)
  • 10. Pre-conceptional diabetes (type 1 or 2)
  • 11. Celiac disease and/or wheat protein allergy of mother
  • 12. Breast surgery and/or hypomastia
  • 13. Mixed feeding at MR 2 (4th week of life)

About Moenie Van Der Kleyn

Moenie van der Kleyn is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Moenie van der Kleyn oversees the design, implementation, and management of clinical trials across various therapeutic areas. The organization emphasizes collaborative partnerships with healthcare professionals, regulatory bodies, and research institutions to ensure adherence to the highest ethical standards and regulatory compliance. Through a robust framework of scientific rigor and patient-centric approaches, Moenie van der Kleyn aims to contribute significantly to the development of safe and effective therapies.

Locations

Graz, Styria, Austria

Patients applied

0 patients applied

Trial Officials

Moenie van der Kleyn, MPH

Study Director

FH Joanneum Hebammen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials